Human growth hormone treatment for children with Prader-Willi syndrome a review of clinical effectiveness, cost-effectiveness, and guidelines
Two previous CADTH reports examined the clinical effectiveness of human growth hormone (hGH) for Prader-Willi Syndrome (PWS) in adolescents and adults. These reports found that treatment with hGH results in improvement in body composition in patients with Prader-Willi syndrome and summarized evidenc...
| Main Authors: | , , |
|---|---|
| Corporate Authors: | , |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa
CADTH
2018, January 25, 2018
|
| Edition: | Version 1.0 |
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Two previous CADTH reports examined the clinical effectiveness of human growth hormone (hGH) for Prader-Willi Syndrome (PWS) in adolescents and adults. These reports found that treatment with hGH results in improvement in body composition in patients with Prader-Willi syndrome and summarized evidence-based guidelines for the treatment of children and adults with PWS. The purpose of this report is to provide an update regarding the clinical effectiveness of hGH in pediatric PWS patients (0 to 19 years) and a summary of cost-effectiveness analyses and recent evidence-based guidelines |
|---|---|
| Physical Description: | 1 PDF file (25 pages) illustration |